The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12 years and older with Hypereosinophilic Syndrome (HES) for ≥ six months without an identifiable non-hematologic secondary cause.
If you are not happy with the results below please do another search
50 search results for:
The global death toll from Covid-19 could double to 2 million before a successful vaccine is widely used and could be even higher without concerted action to curb the pandemic, an official at the World Health Organization said.
Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
A new study published in Nature suggests that with a cellular and molecular map of the healthy human heart, experts may be able to better understand what goes wrong in cardiovascular disease.
Endo said the company was manufacturing Novavax’s experimental Covid-19 vaccine, sending the generic drugmaker’s shares up 10% in trading.
Japanese researchers developed a blood test they say appears to serve as an early warning system for serious cases of Covid-19, and deployed 500 prototype machines to trial its effectiveness nationwide.
Gilead Sciences agreed to pay $97 million to resolve claims from the U.S. government that the company violated the False Claims Act.
The number of novel coronavirus cases in the United States topped 7 million – more than 20% of the world’s total – as Midwest states reported spikes in Covid-19 infections in September, according to a Reuters tally.
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy does not appear to increase the risk of complications during delivery or negatively impact the health of newborns, according to a new JAMA study.
Bristol Myers Squibb announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met primary endpoints of improving disease-free survival (DFS) versus placebo in both all randomized patients and in patients whose tumor cells express PD-L1 ≥1% (programmed death-ligand 1).